Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Stiff

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
American Journal of Cancer Research|November 18, 2024
Cabozantinib inhibits tumor growth in mice with ovarian cancerPatrick J Stiff, Elizabeth Kertowidjojo, Ronald K Potkul, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial resultsLinda S Elting, Ya-Chen Tina Shih, Patrick J Stiff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cellsRichard T Maziarz, Auayporn P Nademanee, Ivana N Micallef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation settingPatrick J Stiff, Christos Emmanouilides, William I Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trialPatrick J Stiff, Joseph M Unger, Stephen J Forman, et al.
Leukemia & Lymphoma|September 1, 2020
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimenPatrick Hagen, Anita D'Souza, Parameswaran Hari, et al.
Journal of Ovarian Research|May 31, 2018
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancerMaureen L Drakes, Swati Mehrotra, Monica Aldulescu, et al.
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphomaJohn F DiPersio, Ivana N Micallef, Patrick J Stiff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 12, 2012
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trialAuayporn P Nademanee, John F DiPersio, Richard T Maziarz, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
American Journal of Cancer Research|November 18, 2024
Cabozantinib inhibits tumor growth in mice with ovarian cancerPatrick J Stiff, Elizabeth Kertowidjojo, Ronald K Potkul, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2007
Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial resultsLinda S Elting, Ya-Chen Tina Shih, Patrick J Stiff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 22, 2013
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cellsRichard T Maziarz, Auayporn P Nademanee, Ivana N Micallef, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation settingPatrick J Stiff, Christos Emmanouilides, William I Bensinger, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2003
The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trialPatrick J Stiff, Joseph M Unger, Stephen J Forman, et al.
Leukemia & Lymphoma|September 1, 2020
Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimenPatrick Hagen, Anita D'Souza, Parameswaran Hari, et al.
Journal of Ovarian Research|May 31, 2018
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancerMaureen L Drakes, Swati Mehrotra, Monica Aldulescu, et al.
Transplantation|July 23, 2008
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorderLode J Swinnen, Michael LeBlanc, Thomas M Grogan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphomaJohn F DiPersio, Ivana N Micallef, Patrick J Stiff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 12, 2012
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trialAuayporn P Nademanee, John F DiPersio, Richard T Maziarz, et al.
Pageof 8